Literature DB >> 10411932

Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor.

K Abe1, M Shoji, J Chen, A Bierhaus, I Danave, C Micko, K Casper, D L Dillehay, P P Nawroth, F R Rickles.   

Abstract

Tissue factor (TF), a transmembrane receptor for coagulation factor VII/VIIa, is aberrantly expressed in human cancers. We demonstrated a significant correlation between TF and vascular endothelial growth factor (VEGF) production in 13 human malignant melanoma cell lines (r(2) = 0.869, P < 0.0001). Two of these cell lines, RPMI-7951, a high TF and VEGF producer, and WM-115, a low TF and VEGF producer, were grown s.c. in severe combined immunodeficient mice. The high-producer cell line generated solid tumors characterized by intense vascularity, whereas the low producer generated relatively avascular tumors, as determined by immunohistologic staining of tumor vascular endothelial cells with anti-von Willebrand factor antibody. To investigate the structure-function relationship of TF and VEGF, a low-producer melanoma cell line (HT144) was transfected with a TF cDNA containing the full-length sequence, a cytoplasmic deletion mutant lacking the coding sequence for the distal three serine residues (potential substrates for protein kinase C), or an extracellular domain mutant, which has markedly diminished function for activation of factor X. Cells transfected with the full-length sequence produced increased levels of both TF and VEGF. Transfectants with the full-length sequence and the extracellular domain mutant produced approximately equal levels of VEGF mRNA. However, cells transfected with the cytoplasmic deletion mutant construct produced increased levels of TF, but little or no VEGF. Thus, the cytoplasmic tail of TF plays a role in the regulation of VEGF expression in some tumor cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411932      PMCID: PMC17573          DOI: 10.1073/pnas.96.15.8663

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

Review 1.  The structural biology of expression and function of tissue factor.

Authors:  T S Edgington; N Mackman; K Brand; W Ruf
Journal:  Thromb Haemost       Date:  1991-07-12       Impact factor: 5.249

2.  Signal transduction via the mitogen-activated protein kinase pathway induced by binding of coagulation factor VIIa to tissue factor.

Authors:  L K Poulsen; N Jacobsen; B B Sørensen; N C Bergenhem; J D Kelly; D C Foster; O Thastrup; M Ezban; L C Petersen
Journal:  J Biol Chem       Date:  1998-03-13       Impact factor: 5.157

3.  Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII.

Authors:  V Ollivier; S Bentolila; J Chabbat; J Hakim; D de Prost
Journal:  Blood       Date:  1998-04-15       Impact factor: 22.113

4.  Coagulation factors VII and X induce Ca2+ oscillations in Madin-Darby canine kidney cells only when proteolytically active.

Authors:  E Camerer; J A Rottingen; J G Iversen; H Prydz
Journal:  J Biol Chem       Date:  1996-11-15       Impact factor: 5.157

5.  Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis.

Authors:  B M Mueller; W Ruf
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

6.  Tissue factor expression correlates with histological grade in human pancreatic cancer.

Authors:  A K Kakkar; N R Lemoine; M F Scully; S Tebbutt; R C Williamson
Journal:  Br J Surg       Date:  1995-08       Impact factor: 6.939

7.  Protein kinase C alpha activates RAF-1 by direct phosphorylation.

Authors:  W Kolch; G Heidecker; G Kochs; R Hummel; H Vahidi; H Mischak; G Finkenzeller; D Marmé; U R Rapp
Journal:  Nature       Date:  1993-07-15       Impact factor: 49.962

8.  Tissue factor residues 157-167 are required for efficient proteolytic activation of factor X and factor VII.

Authors:  W Ruf; D J Miles; A Rehemtulla; T S Edgington
Journal:  J Biol Chem       Date:  1992-11-05       Impact factor: 5.157

9.  The cytoplasmic domain of tissue factor is phosphorylated by a protein kinase C-dependent mechanism.

Authors:  T F Zioncheck; S Roy; G A Vehar
Journal:  J Biol Chem       Date:  1992-02-25       Impact factor: 5.157

10.  Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration.

Authors:  M Clauss; M Gerlach; H Gerlach; J Brett; F Wang; P C Familletti; Y C Pan; J V Olander; D T Connolly; D Stern
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

View more
  82 in total

Review 1.  Protease-activated receptor 2 signaling in inflammation.

Authors:  Andrea S Rothmeier; Wolfram Ruf
Journal:  Semin Immunopathol       Date:  2011-10-06       Impact factor: 9.623

2.  Tissue factor in predicted severe acute pancreatitis.

Authors:  Ellen Andersson; Jakob Axelsson; Gunilla Eckerwall; Daniel Ansari; Roland Andersson
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

Review 3.  Tissue factor and PAR2 signaling in the tumor microenvironment.

Authors:  Florence Schaffner; Wolfram Ruf
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-08-06       Impact factor: 8.311

4.  Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor.

Authors:  Emiliano Cocco; Joyce Varughese; Natalia Buza; Stefania Bellone; Ken-Yu Lin; Marta Bellone; Paola Todeschini; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Luisa Carrara; Renata Tassi; Sergio Pecorelli; Charles J Lockwood; Alessandro D Santin
Journal:  Clin Exp Metastasis       Date:  2011-07-02       Impact factor: 5.150

Review 5.  The hypercoagulable state of malignancy: pathogenesis and current debate.

Authors:  Graham J Caine; Paul S Stonelake; Gregory Y H Lip; Sean T Kehoe
Journal:  Neoplasia       Date:  2002 Nov-Dec       Impact factor: 5.715

6.  Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?

Authors:  Simone Kayser; Iris Watermann; Christine Rentzsch; Toni Weinschenk; Diethelm Wallwiener; Brigitte Gückel
Journal:  J Cancer Res Clin Oncol       Date:  2003-06-26       Impact factor: 4.553

7.  Cross-talk of integrin alpha3beta1 and tissue factor in cell migration.

Authors:  Andrea Dorfleutner; Edith Hintermann; Takehiko Tarui; Yoshikazu Takada; Wolfram Ruf
Journal:  Mol Biol Cell       Date:  2004-07-14       Impact factor: 4.138

Review 8.  Targeting of drugs and nanoparticles to tumors.

Authors:  Erkki Ruoslahti; Sangeeta N Bhatia; Michael J Sailor
Journal:  J Cell Biol       Date:  2010-03-15       Impact factor: 10.539

9.  Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model.

Authors:  T C Carneiro-Lobo; S Konig; D E Machado; L E Nasciutti; M F Forni; I M B Francischetti; M C Sogayar; R Q Monteiro
Journal:  J Thromb Haemost       Date:  2009-07-17       Impact factor: 5.824

10.  Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease.

Authors:  J E Bluff; S R Menakuru; S S Cross; S E Higham; S P Balasubramanian; N J Brown; M W Reed; C A Staton
Journal:  Br J Cancer       Date:  2009-07-21       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.